Perspective Therapeutics widens loss on every reported line in the latest interim filing

Bottom line

Perspective Therapeutics, Inc. (CATX, CIK 0000728387) filed 10-Q for period-ended-2026-06-30 under accession 0001193125-26-342512, and on every reported earnings dimension the three-month and six-month year-to-date periods both printed losses larger than the prior-year comparisons. Across the three-month reporting period versus the prior-year three-month period, Earnings Per Share, Diluted of -$0.22 per diluted share USD/SHARES compares with -$0.29 per diluted share USD/SHARES, an authorized increase that nonetheless remains a loss. The same pattern holds for the six-month year-to-date period versus its prior-year comparison, where Earnings Per Share, Diluted of -$0.47 per diluted share USD/SHARES compares with -$0.54 per diluted share USD/SHARES, again an authorized increase that stays negative. Net Income (Loss) Attributable to Parent moved in the opposite direction, falling to -$26,786,000 USD for the three-month reporting period from -$21,485,000 USD, and to -$52,975,000 USD for the six-month year-to-date period from -$39,662,000 USD. Operating Income (Loss) tells the same story: a wider loss of -$29,258,000 USD for the three-month reporting period versus -$24,039,000 USD, and -$57,539,000 USD for the six-month year-to-date period versus -$45,871,000 USD. The reader-facing shape is therefore consistent across all three headlines — earnings per share moved upward while net loss and operating loss widened — and the per-share figure is the only series that did not deteriorate year over year.

Source scope for this section is the financial statements section of the quarterly report, accessed through Item Item 1 of the filing, and the accounting policies in the cited note Note 2 attached to those statements. The forward-looking narrative that opens the filing is treated as management commentary rather than fact, and the stockholder-equity discussion in the cited note Note 10 is available for cross-reference but is not a substitute for the headline figures. Other Parts of the report — Item Item 1A on Risk Factors, Item Item 3 on market risk, Item Item 4 on Controls and Procedures, Item Item 5 on Other Information, Item Item 6 on Exhibits, and Item Item 8 on material changes — are outside the financial scope of this section and do not enter the figures above. The deferred-tax discussion in the cited note Note 3 is similarly out of scope here. The filing evidence contains no peer or industry comparison.

Financial performance

- For the three-month reporting period, Perspective Therapeutics, Inc. (CATX) recorded a Net Income (Loss) Attributable to Parent of -$26,786,000 USD, compared with -$21,485,000 USD in the prior-year quarter; both periods were losses and the year-over-year direction is a wider loss. - For the six-month year-to-date period, the same line item was -$52,975,000 USD, against -$39,662,000 USD in the prior year-to-date window; the year-over-year direction is also a wider loss, and the period stayed in a loss-to-loss transition.

- Operating Income (Loss) for the quarter was -$29,258,000 USD, versus -$24,039,000 USD in the prior-year quarter; the year-over-year direction is a wider operating loss, in a loss-to-loss transition. - Operating Income (Loss) for the half year was -$57,539,000 USD, against -$45,871,000 USD in the prior year-to-date window; the year-over-year direction is a wider operating loss, again in a loss-to-loss transition. 29 per diluted share USD/SHARES in the prior-year quarter; both periods were losses, and the year-over-year direction is a smaller per-share loss (an authorized increase toward less negative).

54 per diluted share USD/SHARES in the prior year-to-date window; both periods were losses, and the year-over-year direction is a smaller per-share loss (also an authorized increase toward less negative, in a loss-to-loss transition). - Within this filing (10-Q for period-ended-2026-06-30, accession 0001193125-26-342512, CIK 0000728387), the quarter-over-quarter baselines are not presented as numeric comparatives in the claim set, so the section reports year-over-year only. S.

GAAP, condensed for interim reporting, and intended to be read alongside the most recent annual report on Form referenced within that note. Adjustments are management's view of all normal, recurring items necessary for fair presentation, and the results are not necessarily indicative of full-year outcomes. - Segment information in the filing shows a single operating and reportable segment, the radiopharmaceutical development segment, with segment profit or loss measured as net loss.

The Company currently does not generate revenue from commercial products and incurs the majority of its operating expenses in the United States, and liquidity is discussed in terms of funding operating, investing and financing activities against a history of operating losses and no significant recurring cash inflows. - No forward-looking guidance figures, target margins, or quantified outlook statements are contained in the claim set for this section. - The filing evidence does not attribute this change to any single cause.

- The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. LINKS:

Operating drivers and segments

Perspective Therapeutics, Inc. reports a single operating and reportable segment in this 10-Q filing, identified as its radiopharmaceutical development segment, with segment profit or loss measured as net loss in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Because there is only one segment, the operating-income line on the consolidated statement functions as the segment-level result for both the three-month and six-month windows.

Reported figures: - -$45,871,000 USD for the six months ended June 30, 2025 - -$24,039,000 USD for the three months ended June 30, 2025 - -$57,539,000 USD for the six months ended June 30, 2026 - -$29,258,000 USD for the three months ended June 30, 2026

Both the three-month and the six-month windows are operating losses in the current and prior-year periods, so margin direction is a comparison of loss magnitude rather than a swing between profit and loss. Year over year, operating loss was higher than the prior-year comparative on the six-month basis, and higher than the prior-year comparative on the three-month basis, with both transitions framed as loss-to-loss in the authorized comparisons. No segment-revenue, segment-cost or margin-attribution tables are included in the quoted evidence, so further decomposition within the single segment is not available from the filing.

Management frames Perspective Therapeutics, Inc.'s activities entirely through forward-looking statements about the radiopharmaceutical pipeline rather than through a quarter-specific driver narrative. The discussion in this 10-Q covers timing of discovery programs, preclinical studies and clinical trials, including regulatory communications, submissions and approvals, the belief that manufacturing infrastructure will meet future clinical and commercial demand at major treatment centers, plans to expand supply, manufacturing and distribution capabilities, and expectations regarding the functionality and commercial potential of product candidates. Management also references estimates of ongoing losses, future revenue and capital requirements, the sufficiency of cash resources to fund current planned clinical milestones and operational investments into late The filing evidence does not attribute this change to any single cause. (in this section the relevant phrase is the sufficiency-of-cash claim, which is forward-looking rather than a retrospective cause), and competitive positioning. Risk-factor cross-references point to the Annual Report on Form period-ended-2026-06-30 filing, while the forward-looking-statements framing appears under Item 2 and the risk-factors discussion under Item 1A.

Independent analysis versus management claims: The filing offers operating-loss totals at the consolidated level only, without a management-attributed bridge between this period's loss and the prior-year loss. The filing evidence does not attribute this change to any single cause. The forward-looking statements describe clinical, manufacturing and financing intentions rather than retrospective causes for the year-over-year change in operating loss, so an independent margin-pressure or cost-driver narrative cannot be supported from the quoted evidence. Readers weighing the sufficiency-of-cash claim can cross-check the resulting operating outcome using an ROI Calculator, though no such figure is reproduced here.

Counter-evidence and unknowns: The filing evidence contains no peer or industry comparison. The filing does not contain revenue, cost-of-revenue or operating-expense sub-totals tied to the operating-loss line, so segment-level margin decomposition, peer benchmarking, and any quantitative cause of the loss expansion are not available in the quoted evidence. Item-by-item detail referenced in the cover-page index is not fully reproduced in the quoted text: the financial-statements item (Item 1), the controls-and-procedures discussion (Item 4), the quantitative-and-qualitative-disclosures item (Item 3), the other-information and exhibits items (Item 5 and Item 6), and the material-changes note (Item 8) are acknowledged in the index but their contents are not reproduced here, so specific qualitative drivers cited by management elsewhere in the document cannot be confirmed from this excerpt. Accounting-policy detail in Note 2, the deferred-tax and other-noncurrent-liabilities detail in Note 3, and the preferred-stock disclosure in Note 10 likewise do not speak to the operating-loss movement.

Cash flow and capital

- Perspectum Therapeutics continues to run on financing, with a cash burn profile that shows no commercial revenue support. For the six months ended June 30, 2026, -$52,118,000 was negative, slightly less negative than the prior-year comparable -$41,535,000, consistent with the authorized direction decrease from a loss to a loss. The recurring outflow reflects a company still firmly in the development stage: management explicitly notes in the Liquidity discussion a history of operating losses and an absence of significant recurring cash inflows from revenue.

- Investing activity remained a net use of cash for the six months ended June 30, 2026, reported at -$94,534,000, smaller in magnitude than the prior-year comparable -$1,301,000. Inside that investing line, capital spending, captured as Payments to Acquire Property, Plant, and Equipment, ran at $21,053,000 for the six months ended June 30, 2026, modestly above the prior-year comparable $5,682,000. The pattern suggests continued, deliberate build-out of radiopharmaceutical development infrastructure rather than a retrenchment.

- Financing activity stayed positive on both sides of the comparison. Net Cash Provided by Financing Activities ran at $164,511,000 for the six months ended June 30, 2026, higher than the prior-year comparative $10,105,000. The narrative attributes the inflow to capital markets activity: a completed underwritten offering and an active at-the-market program through the ATM Agents, providing an equity-funded bridge while the operating burn continues.

The filing evidence does not attribute this change to any single cause. - On the balance sheet as of the balance sheet date of June 30, 2026, liquidity is anchored by Cash and Cash Equivalents of $48,488,000, presented at carrying value. Working-capital obligations on the same date consist of Accounts Payable and Accrued Liabilities, Current, at $29,418,000, against Accounts Receivable, after Allowance for Credit Loss, Current of $269,000.

The receivable balance is small relative to the cash position and the payables stack, reinforcing the picture of a pre-commercial issuer whose inflows are episodic and equity-driven rather than customer-driven. - Capital allocation priorities are clearly set in management's own words: the CEO, acting as CODM, regularly reviews scientific data from clinical and preclinical studies and forecasted expenses for continuing operations to decide how to deploy resources. The single operating segment, the radiopharmaceutical development segment, ties that capital story tightly to pipeline progress rather than to commercial returns.

- Management also addresses runway explicitly, stating that the cash, cash equivalents and short-term investments on hand at the balance sheet date are expected to fund current planned operations into the late portion of the forward planning horizon, while warning that the operating plan may change as factors currently unknown to management evolve. The filing reiterates that additional capital may be raised through equity offerings, debt financings, collaborations, strategic alliances, marketing, distribution or licensing arrangements, and government funding or grants.

The filing evidence does not attribute this change to any single cause. - The going-concern language is softer than a full qualification but is present: the unaudited condensed consolidated financial statements are prepared on a going concern basis, contemplating realization of assets and satisfaction of liabilities in the ordinary course of business, and no adjustments have been recorded for potential unknown factors. Investors weighing runway can cross-check assumptions about returns on deployed capital with the ROI Calculator before acting on the narrative.

Peer and historical context

- Across both reported windows for Perspective Therapeutics, Inc. (CATX, filing 10-Q for period-ended-2026-06-30, accession 0001193125-26-342512, CIK 0000728387), the only year-over-year history the catalog authorizes is internal: each metric compared with its own prior-year period rather than against named peers. - The operating-loss trajectory over the half-year window is consistent with the firm's stated history of recurring operating losses and the absence of significant recurring revenue cash inflows disclosed in the liquidity narrative, which together frame the half-year results as a continuation of a pre-existing pattern rather than a one-off quarter. - The authorized loss-to-loss transitions on net income and operating income at both the half-year and quarter level, paired with the authorized decrease in operating cash outflow versus the prior-year six-month period, suggest the cash-burn profile softened even as the income statement widened its loss — a pattern typical of clinical-stage companies whose R&D and pipeline spending schedules are lumpy, though the filing evidence does not attribute this to any single cause. - The filing evidence contains no peer or industry comparison. - The filing also does not disclose segment-level detail for this dimension, so any cross-business unit read across the comparison would be unsupported. - The cash balance disclosed in the liquidity narrative is described qualitatively as sufficient only into a later point in time, and management notes the operating plan may change as a result of many factors currently unknown to management, which qualifies the historical-comparison read by signaling forward-period uncertainty that is not captured in the trailing year-over-year lines.

The half-year operating result registered a loss wider than the prior-year half-year loss on the operating-income line, while the quarterly operating result also printed a loss wider than the prior-year quarter, in each case holding the loss-to-loss transition the catalog authorizes. Net income attributable to parent followed the same pattern in both windows: a larger six-month loss than the prior-year six-month period and a larger three-month loss than the prior-year three-month period, again on the authorized loss-to-loss transitions.

Cash-flow activity tells a different story against the same prior-year six-month base. Net cash used in operating activities over the six-month window decreased in outflow magnitude relative to the prior-year six-month period, while the earnings line above moved in the opposite direction. The filing evidence does not attribute this divergence to any single cause. The reader-facing reconciliation between the wider reported losses and the smaller cash burn would ordinarily come from non-cash items, working-capital movement, or the timing of operating payments, but the filing's commentary in the quoted narrative does not break that bridge down, so any explanation in this section would be unsupported.

The historical-comparison frame is further limited by what the filing does not contain. There is no peer-set benchmark, no industry index reference, and no segment decomposition that would let a reader cross-check the trajectory against a comparable group of radiopharmaceutical or clinical-stage issuers. The only year-over-year anchors are the filing's own prior-period columns.

Investors looking to size the loss against an external benchmark can frame the gap qualitatively using general return-on-investment tooling, such as the ROI Calculator, but the underlying inputs still come only from this filing's own columns rather than from a curated peer set. No quantitative peer benchmark is asserted here.

Scenario analysis

- Reported facts: Net Income (Loss) Attributable to Parent for Perspective Therapeutics, Inc. was a loss of -$26,786,000 USD for the three months ended June 30, 2026 and a loss of -$52,975,000 USD for the six months ended June 30, 2026; the prior-year comparatives were losses of -$21,485,000 USD and -$39,662,000 USD for the three months ended June 30, 2025 and the six months ended June 30, 2025 respectively, with the authorized direction indicating a wider loss on both reported windows. - Management explanations: The filing describes an underwritten offering of common stock and pre-funded warrants, an at-the-market agreement under which the ATM Agents may sell ATM Shares, and the Lantheus Investment Agreement pursuant to which Lantheus Alpha Therapy, LLC acquired Lantheus Shares in a private placement that closed on a later date in the same month, conditional on the Company raising a qualifying third-party financing threshold. Pre-funded warrants are included in basic and diluted earnings per share because their exercise price is nominal, while common stock warrants and options are excluded as antidilutive given the net loss position. - Analyst inference: The capital-raise infrastructure described (the cited underwritten offering, the cited ATM agreement, and the Lantheus private placement) is consistent with continued funding of operating losses rather than near-term breakeven, so a base case would project ongoing losses at the parent level with continued reliance on equity-linked issuance. - Counter-evidence: None identified in the cited notes; the loss-to-loss transitions at both windows are authorized without an offsetting positive driver in the narrative. - Unknowns: The filing evidence does not disclose revenue, cash runway length, or pipeline milestones, so the base trajectory is presented in qualitative terms only.

- Reported facts: Same loss values for -$26,786,000 and -$52,975,000 versus -$21,485,000 and -$39,662,000; the Lantheus Closing occurred once the third-party financing threshold was satisfied in the qualifying transaction on a later date within the same month. - Management explanations: Pro rata participation rights and board observer and information rights granted to Lantheus under the cited investment agreement are framed as supportive of a strategic alignment. - Analyst inference: An upside case would depend on factors the filing does not quantify, such as successful pipeline advancement or capital deployment efficiency from the cited offerings. - Counter-evidence: The authorized direction for Net Income (Loss) Attributable to Parent is decrease on both windows, indicating a wider loss rather than improvement. - Unknowns: Pipeline progression, regulatory timing, and capital allocation outcomes are not disclosed in the cited notes; readers can model return-on-capitalized-research assumptions with ROI Calculator when forming their own view.

- Reported facts: Wider losses on both reported windows per the authorized direction; Operating Income (Loss) is also authorized as decrease with a loss-to-loss transition on both windows; Net Cash Provided by (Used in) Operating Activities and Net Cash Provided by (Used in) Investing Activities are both authorized as decrease (current and prior both negative), while Net Cash Provided by (Used in) Financing Activities is authorized as increase with both periods positive; Payments to Acquire Property, Plant, and Equipment are authorized as increase with both periods positive. - Management explanations: The ATM agreement permits the Company to suspend offers or terminate at any time, leaving equity-linked funding optional rather than committed. - Analyst inference: A downside case would contemplate widening operating cash usage alongside higher property, plant, and equipment outlays, with the option but not the obligation to access the cited ATM Shares as a funding buffer. - Counter-evidence: None identified that would offset the authorized operating-cash and investing-cash deterioration. - Unknowns: The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- The filing evidence does not attribute this change to any single cause. - The most prominent bottom-line risk is the persistence of a parent-level loss in both reported windows. Net Income (Loss) Attributable to Parent for the three-month reporting period was -$26,786,000 USD, compared with a loss of -$21,485,000 USD for the prior-year comparative for the three-month reporting period; the authorized transition is loss to loss and the authorized direction is decrease.

For the six-month year-to-date period, Net Income (Loss) Attributable to Parent was -$52,975,000 USD, against a prior-period loss of -$39,662,000 USD, with the same loss-to-loss transition and a decrease direction. The repeated loss-to-loss framing, on both windows, signals that profitability has not yet been reached at the parent level. - Counter-evidence inside the filing points in the opposite direction on the financing line.

The Management's Discussion and Analysis narrative discloses an at-the-market program (the cited note) under which the Company may issue common stock from time to time, together with a private placement (the cited note) with a strategic investor that closed only after the Company first raised at least the disclosed amount of gross proceeds in a qualifying third-party financing. Those arrangements broaden the capital toolkit beyond a single instrument and align with a research-stage issuer that funds operating losses through equity-linked vehicles, but the disclosure also flags customary commissions on ATM sales, observer and information rights granted to the strategic investor, and pro rata participation rights on future offerings — none of which is quantified in the quoted material.

- Unknowns to flag for readers: revenue mix, segment contribution, geographic split, customer concentration, pipeline composition and per-product economics are not described in the quoted evidence for either reported window, so any read-through from headline loss to product performance is unsupported here. The filing, per the cited note under Item 1A, also states that there have been no material changes to the Company's significant accounting policies from the prior Form referenced under Note 2, leaving policy risk on the table but not active.

- Counter-evidence on internal controls and governance: the cited note under controls and procedures was addressed without a flagged material change in the quoted excerpt, and legal proceedings under the cited note were addressed without a disclosed material proceeding in the quoted excerpt. These are absences rather than confirmations and should be read as such. - Metrics to watch next period: parent-level Net Income (Loss) Attributable to Parent on both windows; operating loss progression; the absolute size and direction of cash used in operating activities and cash used in investing activities, including payments to acquire property, plant, and equipment; and net cash provided by financing activities, given the active ATM and the Lantheus-style strategic placement.

Readers modeling runway and dilution can pressure-test scenarios with the ROI Calculator before the next print.